Mulya.ai
Ticker
IQV
Scenario
Key Inputs
Revenue est.?Analyst
OP margin est.?Analyst
Reinvestment est.?projected
R&D capitalizedNo
Leases factoredNo
Key Assumptions
WACC ?10.5%
ERP ?4.5%
Risk-free rate ?4.1%
Beta (blended) ?1.391
Beta (levered) ?2.028
Terminal OM% ?19.6%
Segment conc. ?55% dominant
Terminal growth ?4.1%
Bond rating ?A- · 1.45%
ROIC option ?Opt 2 · 13.1%
Prob of failure ?0.0%
Pipeline validated · 2026-05-17

IQV · IQVIA Holdings Inc.

$173.262026-05-17
Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Life Sciences Tools & Services

Intrinsic Value Range Comparison · Mulya.ai

Bull
$341
+96.8% vs market
Base · active
$162
-6.3% vs market
Bear
$143
-17.6% vs market
Mulya.ai vs Analyst IV Comparison?
Bear $143
Base $162
Market $173
Median $238
Bull $341
Market Price $173
Mulya.ai Base $162
Analysts Median $238
Mulya.ai IV range ($143 · $341)
Analysts Range ($210 · $258)
Fundamentals · historical + forward · base
italics = DCF projection
PeriodRevenueRev Gr ?Ops M% ?Tax Rate ?NOPAT ?
Reinvest ?
FCFF ?WACC% ?PV FCFF ?ROIC ?Inv. Cap ?EPS ?P/E
2021.Q4$13.9B10.0%14.4%$1.2B−$157MM$1.0B9.7%7.1%$16.7B$5.62
2022.Q4$14.4B3.9%12.5%19.2%$1.5B−$963MM$490MM10.0%8.6%$17.2B$6.35
2023.Q4$15.0B4.0%13.2%6.9%$1.8B−$793MM$1.0B10.1%10.4%$18.3B$7.90
2024.Q4$15.4B2.8%14.3%18.0%$1.8B−$40MM$1.8B10.3%9.9%$18.2B$7.99
2025.Q4$16.3B5.9%14.0%15.6%$1.9B−$427MM$1.5B10.5%10.0%$20.3B$7.9113.0
italics below = DCF projection · 10yr Rev CAGR: 5.4%
2026.Q4$17.2B+5.7%14.1%16.1%$2.0B−$314MM$1.7B10.3%$1.6B10.0%$20.6B$11.9014.6
2027.Q4$18.2B+5.8%14.8%16.5%$2.2B−$364MM$1.9B10.2%$1.6B10.8%$21.0B$13.0813.2
2028.Q4$19.3B+6.0%15.6%16.9%$2.5B−$433MM$2.1B10.0%$1.6B11.8%$21.4B$14.6011.9
2029.Q4$20.6B+6.4%16.3%17.4%$2.8B−$543MM$2.2B9.8%$1.5B12.8%$22.0B$16.1410.7
2030.Q4$21.8B+5.8%16.3%17.8%$2.9B−$583MM$2.3B9.6%$1.5B13.1%$22.5B$16.9910.2
Term. Yr+$28.6B4.1%19.6%20.0%$4.5B−$1.4B$3.1B8.6%$27.4B13.1%
Active scenario IV: $162 (-6.3% vs market)